Simulations Plus, Inc.

Equities

SLP

US8292141053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
41.15 USD -0.48% Intraday chart for Simulations Plus, Inc. -8.02% -8.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Simulations Plus Insider Sold Shares Worth $828,240, According to a Recent SEC Filing MT
Simulations Plus, Inc. Extends Collaboration with Major Toxicology Research Agency CI
Simulations Plus, Inc. Releases GastroPlus Version 9.9 CI
Simulations Plus Insider Sold Shares Worth $889,200, According to a Recent SEC Filing MT
Tranche Update on Simulations Plus, Inc.'s Equity Buyback Plan announced on January 4, 2023. CI
(SLP) SIMULATIONS PLUS Forecasts Fiscal Year 2024 EPS Range $0.66 - $0.68 MT
Earnings Flash (SLP) SIMULATIONS PLUS Reports Q1 Revenue $14.5M, vs. Street Est of $13.9M MT
Simulations Plus, Inc. Declares Cash Dividend, Payable on February 5, 2024 CI
Transcript : Simulations Plus, Inc., Q1 2024 Earnings Call, Jan 03, 2024
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q1 EPS $0.10, vs. Street Est of $0.11 MT
Simulations Plus, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Simulations Plus, Inc. Announces Executive Changes CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited DJ
Transcript : Simulations Plus, Inc. - Analyst/Investor Day
Simulations Plus, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024 CI
Tranche Update on Simulations Plus, Inc.'s Equity Buyback Plan announced on January 4, 2023. CI
Oppenheimer Adjusts Simulations Plus Price Target to $55 From $67, Maintains Outperform Rating MT
Transcript : Simulations Plus, Inc., Q4 2023 Earnings Call, Oct 25, 2023
(SLP) SIMULATIONS PLUS Sees Fiscal Year 2024 EPS Range $0.66 - $0.68 MT
Earnings Flash (SLP) SIMULATIONS PLUS Reports Q4 Revenue $15.6M, vs. Street Est of $16.8M MT
Earnings Flash (SLP) SIMULATIONS PLUS Reports Q4 EPS $0.18 MT
Simulations Plus, Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023 CI
Simulations Plus, Inc. Declares Cash Dividend , Payable on November 6, 2023 CI
Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Simulations Plus, Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Chart Simulations Plus, Inc.
More charts
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.15 USD
Average target price
53.67 USD
Spread / Average Target
+30.42%
Consensus
  1. Stock
  2. Equities
  3. Stock Simulations Plus, Inc. - Nasdaq
  4. News Simulations Plus, Inc.
  5. Insider Trends: 90-Day Insider Selling Trend Continued at Simulations Plus